Centers for Disease Control and Prevention. Shingles (herpes zoster): clinical overview. Atlanta: Centers for Disease Control and Prevention; 2019.

Google Scholar 

Johnson BH, Palmer L, Gatwood J, et al. Annual incidence rates of herpes zoster among an immunocompetent population in the United States. BMC Infect Dis. 2015;15:502.

Article  PubMed  PubMed Central  Google Scholar 

Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82:1341–9.

Article  PubMed  Google Scholar 

Yawn BP, Itzler RF, Wollan PC, et al. Health care utilization and cost burden of herpes zoster in a community population. Mayo Clin Proc. 2009;84:787–94.

Article  PubMed  PubMed Central  Google Scholar 

McKay SL, Guo A, Pergam SA, et al. Herpes zoster risk in immunocompromised adults in the United States: a systematic review. Clin Infect Dis. 2020;71:e125–34.

Article  PubMed  Google Scholar 

Harpaz R, Dahl RM, Dooling KL. Prevalence of immunosuppression among US adults, 2013. JAMA. 2016;316:2547–8.

Article  PubMed  Google Scholar 

United States Census Bureau. Age and sex composition in the United States: 2013. Suitland: United States Government; 2016.

Google Scholar 

Dooling KLGA, Patel M, et al. Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep. 2018;67:103–8.

Article  PubMed  PubMed Central  Google Scholar 

Shingrix [package insert], revised: 07/2021. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2021.

Anderson TC, Masters NB, Guo A, et al. Use of recombinant zoster vaccine in immunocompromised adults aged ≥ 19 years: Recommendations of the Advisory Committee on Immunization Practices—United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:80–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Curran D, Patterson B, Varghese L, et al. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States. Vaccine. 2018;36:5037–45.

Article  CAS  PubMed  Google Scholar 

Curran D, Patterson BJ, Van Oorschot D, et al. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live. Hum Vaccin Immunother. 2019;15:765–71.

Article  PubMed  PubMed Central  Google Scholar 

Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316:1093–103.

Article  PubMed  Google Scholar 

United States Bureau of Labor Statistics. Consumer Price Index for all urban consumers, 2020. Accessed 7 Feb 2020.

United States Bureau of Labor Statistics. Consumer Price Index for medical care. Washington, DC: United States Bureau of Labor Statistics; 2020. Accessed 7 Feb 2020.

Center for International Blood and Marrow Transplant Research. Transplant activity report, 2019. Milwaukee: Center for International Blood and Marrow Transplant Research

Chen SY, Suaya JA, Li Q, et al. Incidence of herpes zoster in patients with altered immune function. Infection. 2014;42:325–34.

Article  PubMed  Google Scholar 

Habel LA, Ray GT, Silverberg MJ, et al. The epidemiology of herpes zoster in patients with newly diagnosed cancer. Cancer Epidemiol Biomark Prev. 2013;22:82–90.

Article  Google Scholar 

Bastidas A, de la Serna J, El Idrissi M, et al. Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial. JAMA. 2019;322:123–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dagnew AF, Ilhan O, Lee WS, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis. 2019;19:988–1000.

Article  CAS  PubMed  Google Scholar 

Curran D, Matthews S, Rowley SD, et al. Recombinant zoster vaccine significantly reduces the impact on quality of life caused by herpes zoster in adult autologous hematopoietic stem cell transplant recipients: a randomized placebo-controlled trial (ZOE-HSCT). Biol Blood Marrow Transplant. 2019;25:2474–81.

Article  CAS  PubMed  Google Scholar 

Eriksson J, Hunger M, Bourhis F, et al. Cost and utility in immunocompromised subjects who developed herpes zoster during the randomized V212 Inactivated Varicella-Zoster Vaccine (ZVIN) trial. Exp Rev Pharmacoecon Outcomes Res. 2020;20(6):613–21.

Article  Google Scholar 

Sahoo F, Hill JA, Xie H, et al. Herpes zoster in autologous hematopoietic cell transplant recipients in the era of acyclovir or valacyclovir prophylaxis and novel treatment and maintenance therapies. Biol Blood Marrow Transplant. 2017;23:505–11.

Article  CAS  PubMed  Google Scholar 

Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375:1019–32.

Article  CAS  PubMed  Google Scholar 

Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372:2087–96.

Article  PubMed  Google Scholar 

Organ Procurement and Transplantation Network. National data, 2021. US Department of Health and Human Services. Accessed 12 Jan 2021.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.

Article  PubMed  Google Scholar 

Centers for Disease Control and Prevention. HIV surveillance report, 2018 (updated), vol. 31. Atlanta: Centers for Disease Control and Prevention; 2020.

Google Scholar 

Leidner AJ, Anderson TC, Hong K, et al. Cost-effectiveness analysis of vaccination with recombinant zoster vaccine among hematopoietic cell transplant recipients and persons with other immunocompromising conditions aged 19 to 49 years. Value Health. 2023;26(2):204–15.

Article  PubMed  Google Scholar 

Prosser LA, Harpaz R, Rose AM, et al. A cost-effectiveness analysis of vaccination for prevention of herpes zoster and related complications: input for national recommendations. Ann Intern Med. 2019;170:380–8.

Article  PubMed  Google Scholar 

Carpenter CF, Aljassem A, Stassinopoulos J, et al. A cost-effectiveness analysis of an adjuvanted subunit vaccine for the prevention of herpes zoster and post-herpetic neuralgia. Open Forum Infect Dis. 2019;6:ofz219.

Article  PubMed  PubMed Central  Google Scholar 

Le P, Rothberg MB. Cost-effectiveness of the adjuvanted herpes zoster subunit vaccine in older adults. JAMA Intern Med. 2018;178:248–58.

Article  PubMed  PubMed Central  Google Scholar 

Seo H-MKY, Bang CH, et al. Antiviral prophylaxis for preventing herpes zoster in hematopoietic stem cell transplant recipients: a systematic review and meta-analysis. Antivir Res. 2017;140:106–15.

Article  CAS  PubMed  Google Scholar 

Neumann PJ, Kim DD. Cost-effectiveness thresholds used by study authors, 1990–2021. JAMA. 2023;329(15):1312–4.

Article  PubMed  PubMed Central  Google Scholar 

Winston DJ, Mullane KM, Cornely OA, et al. Inactivated varicella zoster vaccine in autologous haemopoietic stem cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391:2116–27.

Article  PubMed  Google Scholar 

Zhang D, Weiss T, Feng Y, et al. Duration of antiviral prophylaxis and risk of herpes zoster among patients receiving autologous hematopoietic stem cell transplants: a retrospective, observational study. Adv Ther. 2017;34:1610–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Le P, Rothberg MB. Cost-effectiveness of herpes zoster vaccine for persons aged 50 years. Ann Intern Med. 2015;163:489–97.

Article  PubMed  Google Scholar 

Blank LJ, Polydefkis MJ, Moore RD, et al. Herpes zoster among persons living with HIV in the current antiretroviral therapy era. J Acquir Immune Defic Syndr. 2012;61:203–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Siddiqi AE, Hall HI, Hu X, et al. Population-based estimates of life expectancy after HIV diagnosis: United States 2008–2011. J Acquir Immune Defic Syndr. 2016;72:230–6.

Article  PubMed  PubMed Central  Google Scholar 

National Cancer Institute. SEER cancer stat facts. Bethesda: National Cancer Institute; 2020.

Google Scholar 

Noone A, Howlader N, Krapcho M, et al. SEER cancer statistics review, 1975–2015. Updated 10 Sep 2018. Bethesda: National Cancer Institute; 2018.

Google Scholar 

Pergam SA, Forsberg CW, Boeckh MJ, et al. Herpes zoster incidence in a multicenter cohort of solid organ transplant recipients. Transpl Infect Dis. 2011;13:15–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kaballo MA, Canney M, O’Kelly P, et al. A comparative analysis of survival of patients on dialysis and after kidney transplantation. Clin Kidney J. 2018;11:389–93.

Article  PubMed  Google Scholar 

Arias E, Xu J. United States life tables: 2017. National vital statistics reports. 2019:68(7).

GSK. ZOSTER-002 annex tables: vaccine efficacy by year [data on file]. GSK; 2020.

GSK. ZOSTER-002 annex tables: frequency of medically attended visit types by time period post vaccination and age group: combined doses (total vaccinated cohort) [data on file]. GSK; 2020.

GSK. ZOSTER-002 clinical study report [data on file]. GSK; 2020.

Vink P, Delgado Mingorance I, Maximiano Alonso C, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: a randomized trial. Cancer. 2019;125:1301–12.

Article  CAS  PubMed